XML 91 R58.htm IDEA: XBRL DOCUMENT v3.20.1
License agreements - Syros (Details)
$ / shares in Units, $ in Thousands, shares in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Jan. 08, 2018
USD ($)
$ / shares
Jan. 01, 2018
USD ($)
$ / shares
shares
Jan. 31, 2018
USD ($)
item
$ / shares
shares
Mar. 31, 2020
USD ($)
Mar. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2019
USD ($)
License agreements              
Long term investments       $ 180,993     $ 133,657 [1]
Research and development expense       1,085,287 $ 270,545    
Unrealized gain (loss) on long term investments       (48,132) 20,989    
Syros Pharmaceuticals, Inc.              
License agreements              
Number of program targets | item     7        
Upfront payment under license agreement     $ 10,000        
Fair market value of our long term investments       $ 5,600     $ 6,500
Ownership percentage (as a percent)       2.00%      
Unrealized gain (loss) on long term investments       $ 900 $ 3,300    
Syros Pharmaceuticals, Inc. | Stock purchase agreement              
License agreements              
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares   0.8          
Purchase price of common stock   $ 10,000          
Per share price | $ / shares $ 9.77 $ 12.61          
Lock-up period 12 months            
Discount for lack of marketability $ 100            
Fair value of shares on the issuance date $ 7,600            
Long term investments           $ 7,600  
Research and development expense           2,400  
Syros Pharmaceuticals, Inc. | Amended stock purchase agreement              
License agreements              
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares     0.1        
Purchase price of common stock     $ 1,400        
Per share price | $ / shares     $ 9.55        
Long term investments           $ 1,400  
Syros Pharmaceuticals, Inc. | Maximum              
License agreements              
Target selection and option exercise fee payment     $ 54,000        
Syros Pharmaceuticals, Inc. | Development and Regulatory Milestones | Maximum              
License agreements              
Additional milestone payments under the license agreement     50,000        
Syros Pharmaceuticals, Inc. | Commercialization Milestones | Maximum              
License agreements              
Additional milestone payments under the license agreement     $ 65,000        
[1] The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements at that date.